Get the latest news, insights, and market updates on PTCT (PTC Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Japan Sephience Approval Could Be A Game Changer For PTC Therapeutics’ (PTCT) Rare-Disease Strategy
Earlier in December, PTC Therapeutics announced that Japan’s Ministry of Health, Labor and Welfare approved Sephience (sepiapterin) for treating children and adults with phenylketonuria, marking the company’s first product approval in Japan and extending its recent PKU launches following authorizations in the US, EU and Canada. This Japanese approval broadens Sephience’s global footprint and could be particularly meaningful given Japan’s historically concentrated rare disease market and... Dec 23, 2025 - $PTCT
PTC Therapeutics (PTCT): Valuation Check After First Japan Approval Completes Global Sephience Launch
PTC Therapeutics (PTCT) just cleared a major milestone in Japan, with regulators approving Sephience for phenylketonuria. This effectively rounds out a global launch after recent US, EU, and Canadian green lights. See our latest analysis for PTC Therapeutics. That global rollout narrative is showing up in the numbers, with the share price at $78.9 and a roughly 72 percent year to date share price return suggesting momentum is building, while the three year total shareholder return of about... Dec 23, 2025 - $PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to five new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. Dec 19, 2025 - $PTCT
PTC Therapeutics (PTCT): Revisiting Valuation After Strong Multi‑Year Share Price Gains
PTC Therapeutics (PTCT) has quietly become a strong performer, with the stock up around 65% this year and more than tripling over the past 3 years, despite choppy near term results. See our latest analysis for PTC Therapeutics. After a sharp run higher, the recent pullback, including a 12.16% 7 day share price decline and near term volatility, looks more like a breather within a still strong uptrend, supported by a 3 year total shareholder return of 97.91%. If PTCT has caught your eye, this... Dec 4, 2025 - $PTCT
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple